These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38172995)

  • 21. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
    Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
    Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
    Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
    Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of once-weekly versus once-daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis.
    Karakasis P; Patoulias D; Pamporis K; Popovic DS; Stachteas P; Bougioukas KI; Fragakis N; Rizzo M
    Diabetes Obes Metab; 2023 Dec; 25(12):3648-3661. PubMed ID: 37667676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
    Lingvay I; Buse JB; Franek E; Hansen MV; Koefoed MM; Mathieu C; Pettus J; Stachlewska K; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1595-1603. PubMed ID: 33875484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in insulin: a review of icodec as a novel once-weekly treatment for type 2 diabetes.
    Morales J; King A; Oser S; D'Souza S
    Postgrad Med; 2024 Oct; ():1-10. PubMed ID: 39348567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials.
    Watada H; Ásbjörnsdóttir B; Nishida T; Nishimura R; Yamamoto Y; Yamauchi T; Kadowaki T
    Diabetes Obes Metab; 2024 Dec; 26(12):5882-5895. PubMed ID: 39344833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes.
    Philis-Tsimikas A; Bajaj HS; Begtrup K; Cailleteau R; Gowda A; Lingvay I; Mathieu C; Russell-Jones D; Rosenstock J
    Diabetes Obes Metab; 2023 Feb; 25(2):331-341. PubMed ID: 36106652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility analysis and drug pricing of once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes patients treated with basal insulin in China.
    Hu S; Wang S; Gu S; Qi C; Shi C; Fan G
    Diabetes Obes Metab; 2024 Dec; 26(12):5995-6006. PubMed ID: 39344844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1.
    Polonsky W; Benamar M; Carstensen L; Davies M; Meller Donatsky A; Franek E; Kellerer M; Philis-Tsimikas A; Goldenberg R
    Diabetes Res Clin Pract; 2024 Nov; 217():111885. PubMed ID: 39368488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials.
    Dutta D; Nagendra L; Bhat S; Mohindra R; Surana V; Misra A
    Diabetes Metab Syndr; 2023 Oct; 17(10):102877. PubMed ID: 37832481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes.
    Bajaj HS; Goldenberg RM
    touchREV Endocrinol; 2023 May; 19(1):4-6. PubMed ID: 37313230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.
    Rosenstock J; Juneja R; Beals JM; Moyers JS; Ilag L; McCrimmon RJ
    Endocr Rev; 2024 May; 45(3):379-413. PubMed ID: 38224978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Icodec ONWARDS: A review of the first once-weekly diabetes treatment for nurse practitioners and physician assistants.
    Kruger D; Magwire M; Urquhart S
    J Am Assoc Nurse Pract; 2024 Oct; ():. PubMed ID: 39412407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Zhou W; Tao J; Zhou X; Chen H
    Diabetes Ther; 2019 Jun; 10(3):835-852. PubMed ID: 31020539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.
    Tricco AC; Ashoor HM; Antony J; Beyene J; Veroniki AA; Isaranuwatchai W; Harrington A; Wilson C; Tsouros S; Soobiah C; Yu CH; Hutton B; Hoch JS; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
    BMJ; 2014 Oct; 349():g5459. PubMed ID: 25274009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.
    Ayesh H; Suhail S; Ayesh S; Niswender K
    Metabol Open; 2024 Jun; 22():100284. PubMed ID: 38699397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological and Benefit-Risk Profile of Once-Weekly Basal Insulin Administration (Icodec): Addressing Patients' Unmet Needs and Exploring Future Applications.
    Ingrasciotta Y; Vitturi G; Trifirò G
    J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
    Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
    Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.